Antiproliferative and phenotype-transforming antitumor agents derived from cysteine

Journal of Medicinal Chemistry

Volumn 47, Issue 12, 2004, Pages 2984-2994

  Glenn, Matthew P ^a   Kahnberg, Pia ^a   Boyle, Glen M ^b   Hansford, Karl A ^a   Hans, Dhiraj ^a   Martyn, Adam C ^b   Parsons, Peter G ^b   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 BUTANOYL HYDROXAMATE; ANTINEOPLASTIC AGENT; BENZYLAMINE; CARBOXYLIC ACID; CYSTEINE; HYDROXAMIC ACID; PROTEIN P21; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; CANCER CELL; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL KILLING; CELL PROLIFERATION; DERIVATIZATION; DRUG POTENCY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA CELL; PHENOTYPE; PROTON NUCLEAR MAGNETIC RESONANCE; TISSUE SPECIFICITY;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; BENZYLAMINES; CARBOXYLIC ACIDS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTEINE; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONES; HUMANS; MODELS, MOLECULAR; PHENOTYPE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2542643987     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030222i     Document Type: Article

References (42)

1. Marks, P. A.; Richon, V. M.; Kiyokawa, H.; Rifkind, R. A. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 10251-10254.
2. Rifkind, R. A.; Richon, V. M.; Marks, P. A. Induced differentiation, the cell cycle and the treatment of cancer. Pharmacol. Ther. 1996, 69, 97-102.
3. Leszczyniecka, M.; Roberts, T.; Dent, P.; Grant, S.; Fisher P. B. Differentiation therapy of human cancer: basic science and clinical implications. Pharmacol. Ther. 2001, 90, 105-156.
4. Vigushin, D. M.; Coombes, R. C. Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs. 2002, 13, 1-13.
5. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nature 2001, 1, 194-202.
6. Richon, V. M.; Emiliani, S.; Verdin, S.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3003-3007.
7. Parsons, P. G.; Hansen, C.; Fairlie, D. P.; West, M. L.; Danoy, P. A. C. ; Sturm, R. A.; Dunn, I. S.; Pedley, J.; Ablett, E. M. Tumor Selectivity and Transcriptional Activation by Azalaic Bishydroxamic Acid in Human Melanocytic Cells. Biochem. Pharmacol. 1997, 53, 1719-1724.
8. Su, G. H.; Sohn, T. A.; Ryu, B.; Kern, S. E. A Novel Histone Deacetylase Inhibitor Identified by High-Troughput Transcriptional Screening of a Compound Library. Cancer Res. 2000, 60, 3137-3142.
9. Butler, L. M.; Agus, D. B.; Sher, H. I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H. T.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. Suberoylanilide Hydroxamic Acid, an inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo. Cancer Res. 2000, 60, 5165-5170.
10. Tsuji, N.; Kobayashi, M.; Nagashima, K.; Wakisaka, Y.; Koizumi, K. A new antifungal antibiotic, trichostatin. J. Antibiot. 1976, 29, 1-6.
11. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specifik Inhibition of Mammalian Histone Deacetylase Both in Vivo and in Vitro by Trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
12. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreverible Inhibitor of Mammalian Histone Deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
13. Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R. W.; Dulski, P. M.; Crumley, T. M.; Allocco, J. J.; Cannova, C.; Meinke, P. T.; Colletti, S. L.; et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Nat. Acad. Sci. U.S.A. 1996, 93, 13143-13147.
14. Yoshida, M.; Furumai, R.; Nishiyama, M.; Komatsu, Y.; Nishino, N.; Horinouchi, S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2001, 48, S20-S26.
15. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Nat. Acad. Sci. U.S.A. 2001, 98, 87-92.
16. Murray, P. J.; Kranz, M.; Ladlow, M.; Taylor, S.; Berst, F.; Holmes, A. B.; Keavey, K. N.; Jaxa-Chamiec, A.; Seale, P. W.; Stead, P.; Upton, R. J.; Croft, S. L.; Clegg, W.; Elsegood, M. R. J. The synthesis of cyclic tetrapeptiod analogues of the antiprotozoal natural product Apicidin. Bioorg. Med. Chem. Lett. 2001, 11, 773-776.
17. Taunton, J.; Collins, J. L.; Schreiber, S. L. Synthesis of Natural and Modified Trapoxins, Useful Reagents for Exploring Histone Deacetylase Function. J. Am. Chem. Soc. 1996, 118, 10412-10422.
18. Komatsu, Y.; Tomizaki, K.; Tsukamoto, M.; Kato, T.; Nishino, N.; Sato, S.; Yamori, T.; Tsuruo, T.; Furumai, R.; Yoshida, M.; Horinouchi, S.; Hayashi, H. Cyclic Hydroxamic-acid-containing Peptide 31, a Potent Synthetic Histone Deacetylase Inhibitor with Antitumor Activity. Cancer Res. 2001, 61, 4459-4460.
19. Cairns B. R. Emerging roles for chromatin remodelling in cancer biology. Trends Cell Biol. 2001, 11, S15-S21.
20. Cress, W. D.; Seto, E. Histone Deacetylase, Transcriptional Control, and Cancer. J. Cell. Physiol. 2000, 184, 1-16.
21. Schlake, T.; Klehr-Wirth, D.; Yoshida, M.; Beppu, T.; Bode, J. Gene expression within a chromatin domain: the role of core histone hyperacetylation. Biochemistry 1994, 33, 4197-4206.
22. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13, 477-483.
23. Grozinger, C. M.; Schreiber, S. L. Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors. Chem. Biol. 2002, 9, 3-16.
24. Johnstone, R. W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nature Rev. 2002, 1, 287-299.
25. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A. ; Marks, P. A.; Breslow, R.; Pavletich, N. P.; Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
26. Marmorstein, R. Structure of Histone Deacetylases: Insights into Substrate Recognition and Catalysis. Structure 2001, 9, 1127-1133.
27. Qiu, L.; Burgess, A.; Fairlie, D. P.; Leonard, H.; Parsons, P. G.; Gabrielli, B. G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell. 2000, 11, 2069-2083.
28. Krämer, O. H.; Göttlicher, M.; Heinzel, T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 2001, 12, 294-300.
29. Saito, S.; Crissman, H. A.; Nishijima, M.; Kagabu, T.; Nishiya, I.; Cram, L. S. Flow cytometric and biochemical analysis of dose-dependent effects of sodium butyrate on human endometrial adenocarcinoma cells. Cytometry 1991, 12, 757-764.
30. Qiu, L.; Kelso, M. J.; Hansen, C.; West, M. L.; Fairlie, D. P.; Parsons, P. G. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 1999, 80, 1252-1258.
31. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13, 477-483.
32. Gregory, P. D.; Wagner, K.; Horz, W. Histone acetylation and chromatin remodeling. Exp. Cell. Res. 2001, 265, 195-202.
33. Van-Lint, C.; Emiliani, S.; Verdin, E. Expression of a small fraction of cellular genes is changed in response to histone acetylation. Gene Express. 1996, 5, 245-253.
34. Richon, V. M.; Sandhoff, T. W.; Rifkind, R. A.; Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 10014-10019.
35. WAF1/CIP1 by Histone Deacetylase Inhibitors Reduces Their Cytotoxicity. Mol. Pharmacol. 2001, 60, 1-10.
36. Warrener, R.; Beamish, H.; Burgess, A.; Waterhouse, N. J.; Giles, N.; Fairlie, D. P.; Gabrielli, B. Tumour cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 2003, 17, 1550-1552.
37. Parsons, P. G.; Bowman, E. P. W.; Blakely, R. L. Selective toxicity of deoxyadenosine analogues in human melanoma cell lines. Biochem. Pharmacol. 1986, 35, 4025-4029.
38. Todaro, G. J.; Fryling, C.; De Larco, J. E. Transforming growth factors produced by certain human tumour cells: polypeptides that interact with epidermal growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 5258-5262.
39. Xu, C.; Parsons, P. G. Cell cycle delay, mitochondrial stress and uptake of hydrophobic cat-ions induced by sunscreens in cultured human cells. Photochem. Photobiol. 1999, 69, 611-616.
40. Chen, T. R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp. Cell. Res. 1977, 104, 255-262.
41. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
42. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, P.; Scudiero, D. A.; Monks, A.; Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 1990, 82, 1113-1118.